Krishna Institute of Medical Sciences Ltd (KIMS) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported good results for Q2 FY26, despite it typically being a slower quarter for the industry.
- Total revenue grew by 23.3% year-on-year and 9.8% quarter-on-quarter, indicating strong top-line expansion.
- EBITDA, however, saw a decline of 6.7% year-on-year, primarily due to the commissioning of almost 4-5 new hospitals that are yet to break even, creating a drag on profitability.
- EBITDA margin stood at 21.6%, a decrease from 28.5% in Q2 FY25 and 22.7% in Q1 FY26, reflecting the impact of new, ramping-up facilities.
- Operational metrics showed positive trends with IP volume growing by 15.3% year-on-year and OP volume increasing by 25.1% year-on-year, demonstrating robust patient footfall.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.